We are monitoring the impact of COVID-19 on APAC Melanoma Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 795
Share on
Share on

Asia Pacific Melanoma Therapeutics Market Research Report - Segmented By Cancer Stage, Cancer Type, Diagnosis, Treatment and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2019 - 2024)

Pulished: February, 2020
ID: 795
Pages: 145

APAC Melanoma Therapeutics Market Size & Growth (2019 - 2024)

The size of the Melanoma Therapeutics Market in the Asia Pacific was worth USD 0.78 billion in 2019 and estimated to be growing at a CAGR of 16.40%, to reach USD 1.66 billion by 2024.

The melanoma market has seen an unparalleled boost in market size, owing to a vigorously developing nature of melanoma treatments over the recent past.

The elevated demand for innovative early-stage and advanced melanoma treatments along with a thriving patient base has generated an imminent need for improved therapies in the melanoma market. Even though a plethora of treatment choices are accessible today, various immunotherapies and combination therapies are anticipated to arrive in the market. Large acceptance of these new treatments is projected due to their enhanced survival benefits and negligible side effects.

The growth of the Asia-Pacific Melanoma Therapeutics market is mainly due to factors such as the rise in the number of melanoma cases, and growing awareness towards it.

However, volatile economies and poor accessibility of proper cancer care in this part of the world are the key factors hindering the growth of the market in this region.

This research report segmented and sub-segmented into the following categories:

  • By Cancer Stage: Stage 0, Stage I, Stage II, Stage III and Stage IV
  • By Cancer Type: Nodular Melanoma, Acral Lentiginous Melanoma, Superficial Spreading Melanoma, Lentigno Maligna Melanoma, Amelanotic Melanoma and Others
  • By Diagnosis: Ultrasound, Blood Tests, Dermatoscopy, Sentinel Lymph Node Biopsy, X-rays and CT Scan
  • By Treatment: Early Melanoma, Advanced Melanoma-Biological Therapy, Targeted Therapy, Surgery, Chemotherapy, Radiotherapy and Immune Therapy
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

The Asia-Pacific Melanoma Therapeutics market is projected to grow at the highest CAGR during the forecast period due to reasons such as a large population base and rising prevalence of melanoma. China is the largest market for Melanoma Therapeutics in this region followed by India.

The Top companies leading in the APAC Melanoma Therapeutics Market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 China                         

              6.3 India                          

              6.4 Japan                         

              6.5 South Korea                            

              6.6 Australia                   

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Melanoma Therapeutics Market By Region, From 2019-2024(USD Billion)
  2. Asia-Pacific Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  3. Asia-Pacific Stage 0 Market By Region, From 2019-2024(USD Billion)
  4. Asia-Pacific Stage I Market By Region, From 2019-2024(USD Billion)
  5. Asia-Pacific Stage II Market By Region, From 2019-2024(USD Billion)
  6. Asia-Pacific Stage III Market By Region, From 2019-2024(USD Billion)
  7. Asia-Pacific Stage IV Market By Region, From 2019-2024(USD Billion)
  8. Asia-Pacific Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  9. Asia-Pacific Nodular melanoma Market By Region, From 2019-2024(USD Billion)
  10. Asia-Pacific Acral lentiginous melanoma Market By Region, From 2019-2024(USD Billion)
  11. Asia-Pacific Superficial spreading melanoma Market By Region, From 2019-2024(USD Billion)
  12. Asia-Pacific Lentigno maligna melanoma Market By Region, From 2019-2024(USD Billion)
  13. Asia-Pacific Amelanotic melanoma Market By Region, From 2019-2024(USD Billion)
  14. Asia-Pacific Other cancers Market By Region, From 2019-2024(USD Billion)
  15. Asia-Pacific Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  16. Asia-Pacific Ultrasound Market By Region, From 2019-2024(USD Billion)
  17. Asia-Pacific Blood Tests Market By Region, From 2019-2024(USD Billion)
  18. Asia-Pacific Dermatoscopy Market By Region, From 2019-2024(USD Billion)
  19. Asia-Pacific Sentinel lymph node biopsy Market By Region, From 2019-2024(USD Billion)
  20. Asia-Pacific X-rays Market By Region, From 2019-2024(USD Billion)
  21. Asia-Pacific CT Scan Market By Region, From 2019-2024(USD Billion)
  22. Asia-Pacific Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  23. Asia-Pacific early melanoma Market By Region, From 2019-2024(USD Billion)
  24. Asia-Pacific advanced melanoma Market By Region, From 2019-2024(USD Billion)
  25. Asia-Pacific Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  26. Asia-Pacific Biological therapy Market By Region, From 2019-2024(USD Billion)
  27. Asia-Pacific Targeted therapy Market By Region, From 2019-2024(USD Billion)
  28. Asia-Pacific Surgery Market By Region, From 2019-2024(USD Billion)
  29. Asia-Pacific Chemotherapy Market By Region, From 2019-2024(USD Billion)
  30. Asia-Pacific Radiotherapy Market By Region, From 2019-2024(USD Billion)
  31. Asia-Pacific Immune therapy Market By Region, From 2019-2024(USD Billion)
  32. China Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  33. China Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  34. China Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  35. China Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  36. China Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  37. India Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  38. India Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  39. India Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  40. India Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  41. India Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  42. Japan Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  43. Japan Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  44. Japan Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  45. Japan Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  46. Japan Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  47. South Korea Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  48. South Korea Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  49. South Korea Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  50. South Korea Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  51. South Korea Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  52. Australia Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  53. Australia Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  54. Australia Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  55. Australia Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  56. Australia Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample